Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19
Status:
Active, not recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
The objectives of the trial are to evaluate the efficacy and safety of trimodulin as add-on
therapy to standard of care (SoC) compared to placebo treatment in adult hospitalized
subjects with severe COVID-19.
Additionally, pharmacodynamic (PD) and pharmacokinetic (PK) properties of trimodulin will be
evaluated in all subjects.